HDAC2: A Potential Drug Target and Biomarker (G3066)

Target Name: HDAC2

NCBI ID: G3066

HDAC2

HDAC2: A Potential Drug Target and Biomarker

Hydroxy-未-acetylase 2 (HDAC2) is a gene that encodes a protein involved in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The HDAC2 gene has been identified as a potential drug target and biomarker for several diseases, and various studies have investigated its function and its potential as a therapeutic approach.

TheHDAC2 gene is a member of the HDAC family, which includes several other genes involved in the regulation of cellular processes, including DNA replication, transcription, and stress responses. The HDAC2 gene is expressed in various tissues and cells throughout the body, including the brain, pancreas, and gastrointestinal tract.

One of the key functions of the HDAC2 gene is its role in the regulation of cellular processes that are associated with aging and age-related diseases. For example, HDAC2 has been shown to play a role in the regulation of cellular senescence, which is the process by which cells become less flexible and more susceptible to damage and disease. In addition, HDAC2 has also been shown to play a role in the regulation of cellular apoptosis, which is the process by which cells undergo programmed cell death in response to various stimuli, including stress and DNA damage.

In addition to its role in cellular processes, HDAC2 has also been shown to be involved in the regulation of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that HDAC2 is involved in the regulation of cancer cell growth and survival, and that it may be a potential therapeutic approach for the treatment of various cancers. In addition, HDAC2 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been shown to play a role in the development of these conditions.

In addition to its potential therapeutic applications, HDAC2 has also been identified as a potential biomarker for several diseases. For example, studies have shown that HDAC2 is involved in the regulation of cellular processes that are associated with aging and age-related diseases, and that it may be a potential biomarker for these conditions. In addition, HDAC2 has also been shown to be involved in the regulation of cellular apoptosis, and has been shown to play a role in the development of certain forms of neurodegenerative disease.

Overall, the HDAC2 gene has been shown to be involved in a wide range of cellular processes that are associated with aging and age-related diseases. As such, it has potential as a drug target and biomarker for several diseases. Further research is needed to fully understand the functions of HDAC2 and its potential as a therapeutic approach.

Protein Name: Histone Deacetylase 2

Functions: Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4) (PubMed:28497810). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events (By similarity). Histone deacetylases act via the formation of large multiprotein complexes (By similarity). Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR (PubMed:12724404). Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development (By similarity). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). Also deacetylates non-histone targets: deacetylates TSHZ3, thereby regulating its transcriptional repressor activity (PubMed:19343227). May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation (By similarity). Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A (PubMed:21965678). In addition to protein deacetylase activity, also acts as protein-lysine deacylase by recognizing other acyl groups: catalyzes removal of (2E)-butenoyl (crotonyl) and 2-hydroxyisobutanoyl (2-hydroxyisobutyryl) acyl groups from lysine residues, leading to protein decrotonylation and de-2-hydroxyisobutyrylation, respectively (PubMed:28497810, PubMed:29192674)

The "HDAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HDAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets